INTRODUCTION

Fear and anxiety are normal emotions in children during growth and development. In some cases, however, fear causes significant distress and functional impairment. Here, we present a case of sophophobia (fear of learning) in an adolescent patient, in whom augmentation of escitalopram with perospirone was useful. This is the first case report of sophophobia. Both the patient and his guardian provided permission to publish the features of his case, and the identity of the patient has been protected.

HISTORY OF PRESENT ILLNESS

At the age of 14, studying elicited anxiety and panic-like symptoms, including shortness of breath, tightness in his chest, and palpitations. As a result, he began to avoid situations that required studying. He had visited another pediatric clinic where lorazepam was started at the dose of 0.5 mg/day, as needed. However, he showed only transient and partial improvement with lorazepam. Lorazepam was discontinued. Hence, he consulted our clinic at the age of 15.

PHYSICAL EXAMINATION

His vital signs were stable and physical examination was unremarkable. His electrocardiogram (ECG) showed normal sinus rhythm. His full blood cell count and laboratory biochemical parameters were normal. He was not on any medications. He was referred to a pediatric cardiologist to rule out a cardiovascular pathology, but there were no abnormal findings, including on Holter ECG recordings.
Sofophobophobia. His score on the Improving Access to Psychological
Maintained. Six months after beginning perospirone, his improvement has been
To 0–2 points. He seemed calm and relieved. Increased feeling of
Creased significantly and did not interfere with his daily studying.
Increased feeling of activation is observable in models of anxiety and depression.13 The 5-
Receptors.14,15 As a result, 5-HT1A agonistic and 5-HT2A blocking
Of specific phobias from 0 (not at all) to 8 (very severely), with a
cutoff of 4 or above indicating the presence of phobias, was 8
Points, which is above the clinical threshold, at the beginning of
His treatment.
5 | TREATMENT

The patient was provided psychoeducation about his condition and was taught guided relaxation techniques, which he found to be very helpful. However, there was only a limited effect on his symptoms. His score on the IAPT-specific phobia scale ranged from 6 to 8 points. After 3 months of treatment, escitalopram 10 mg/day was initiated. Increasing the dose of escitalopram was suggested, but he felt anxious about increasing the dose beyond 15 mg/day. Although he showed gradual improvement with this treatment, there was only a limited effect on his symptoms. At this time, his IAPT-specific phobia scale score ranged from 4 to 8 points. The patient was referred for psychotherapy, but he was unable to attend sessions. His symptoms had not improved, and he seemed to be so tense and exhausted. After 10 months of treatment with escitalopram, risperidone 0.5 mg/day was initiated as an add-on treatment to augment the escitalopram effect, although it was soon discontinued because it was ineffective and caused drowsiness. Instead, perospirone 4 mg/day was added. After 4 weeks, his fear had decreased significantly and did not interfere with his daily studying. His IAPT-specific phobia scale score was significantly improved to 0–2 points. He seemed calm and relieved. Increased feeling of calmness and relaxation was also reported from him and his family. Six months after beginning perospirone, his improvement has been maintained.

6 | DISCUSSION

The word sofophobophobia is made up of 2 Greek words, Sophia and phobia. Sophia means wisdom.2 Thus, sofophobophobia is the fear of learning or of knowledge. According to the DSM-5, there are certain specific phobia types: animal, natural environment, blood-injection-injury, situational, and others. Sofophobophobia is categorized as a specific phobia under the “others” category.1 However, sofophobophobia has only been rarely reported, and little is known about it. Bullying might be a cause of sofophobophobia, since a child who is bullied in school might be afraid of learning. In this case, the patient’s parents did not report bullying. Sofophobophobia can also be triggered by a learning disability. In this case, the patient’s intellectual functioning was normal and there seemed to be no other learning difficulty.

Previously, the efficacy of cognitive behavioral therapy (CBT) for the treatment of childhood- and adolescent-specific phobias was reported.3 However, this patient was unable to attend psychotherapy sessions, probably because he found the CBT session similar to a “learning” situation. The evidence base for pharmacotherapy for childhood- and adolescent-specific phobias, either as stand-alone treatments or in combination with psychological treatments, is limited. Only one small monopharmacotherapy trial included youths with primary specific phobia diagnoses.5 This trial examined the efficacy of fluoxetine treatment. Although Selective Serotonin Reuptake Inhibitors (SSRIs) represent first-line pharmacotherapy for anxious youths,5–8 in pediatric anxiety disorders, escitalopram was superior to placebo in reducing anxiety symptoms.9 Escitalopram was also well-tolerated, similar to other SSRIs, in pediatric anxiety disorders.10 In this case, escitalopram was partially effective and had no obvious adverse effects, including activation.

Perospirone is an atypical antipsychotic available in Japan, that is a partial serotonin (5-HT)1A receptor agonist, and a 5-HT2A, dopamine (D2), and α1 adrenergic receptor antagonist.11,12 The 5-HT1A activation is observable in models of anxiety and depression.13 The 5-HT2A receptors have opposing effects as the postsynaptic 5-HT1A receptors, which enhances the action of serotonin at the 5-HT1A receptors.14,15 As a result, 5-HT1A agonistic and 5-HT2A blocking action may exert anxiolytic and antidepressant effects. Thus, augmentation of SSRIs with perospirone has been used in cases of refractory obsessive-compulsive disorder16,17 and treatment-resistant major depressive disorders.18 In this case, augmentation with perospirone resulted in clinical improvement with no obvious adverse effects, including extrapyramidal symptoms. The precise mechanism involved in adding perospirone to escitalopram and its effect on phobic symptoms is unclear; pharmacological effects of perospirone on 5-HT1A and 5-HT2A receptors may increase serotonergic activity which is considered in the improvement of phobic symptom. And α1-receptor antagonism which is associated with sedation may also be effective to calm and get relieved.19

Aripiprazole, characterized by partial agonism to D2, 5-HT1A and antagonism to 5-HT2A, may be beneficial in this case.20 However, aripiprazole shows the lowest affinity to α1 adrenergic receptors
among all atypical antipsychotics,²¹ which means less sedative effect. Tandospirone, characterized by partial agonism to 5-HT1A, may be also beneficial in this case;²² however, with the combination of Tandospirone with SSRI, clinicians must pay attention to serotonin syndrome.²³

Research on pharmacological approaches for treating childhood and adolescent phobias is limited. This case suggests the possible efficacy of a pharmacological approach to the treatment of phobias in young patients who do not respond to psychotherapeutic approaches. However, further research and investigation are needed on this topic.

CONFLICT OF INTEREST
The author declares no conflict of interest.

DATA AVAILABILITY STATEMENT
Data sharing is not applicable to this article as no datasets were generated or analyzed during the current study.

APPROVAL OF THE RESEARCH PROTOCOL BY AN INSTITUTIONAL REVIEW BOARD
The ethics committee is not required to review case reports.

INFORMED CONSENT
The patient and his guardian gave written consent for publication of this case report.

ORCID
Kensuke Miyazaki https://orcid.org/0000-0002-6277-8200

REFERENCES
1. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 5th ed. Washington, DC: American Psychiatric Association; 2013.
2. National Collaborating Center for Mental Health. The IAPT data handbook on recording and monitoring outcomes to support local evidence-based practice. Version 2.0. 2011. Available at: http://webarchive.nationalarchives.gov.uk/20160302160058/http://www.iapt.nhs.uk/silo/files/iapt-data-handbook-v2.pdf
3. Andrew MC. A dictionary of psychology. 4th ed. Oxford: Oxford University Press; 2015.
4. Davis TE III, Ollendick TH. Empirically supported treatments for specific phobia in children: do efficacious treatments address the components of a phobic response? Clin Psychol. 2005;12(2):144–60.
5. Janet F, Daniel SP, Nancy KT, E. Steven D, Lisa MK, Jacqueline M, et al. Open fluoride treatment of mixed anxiety disorders in children and adolescents. J Child Adolesc Psychopharmacol. 2009;7(1):17–29.
6. Walkup JT, Albano AM, Picentini J, Birmaher B, Compton SN, Sherrill JT, et al. Cognitive behavioral therapy, sertraline, or a combination in childhood medication. N Engl J Med. 2008;359(26):2753–66.
7. Rynn MA, Siqueland L, Rickels K. Placebo-controlled trial of sertraline in the treatment of children with generalized anxiety disorder. Am J Psychiatry. 2001;158(12):2008–14.
8. Wagner KD, Berard R, Stein MB, Wetherhold E, Carpenter DJ, Perera P, et al. A multicenter, randomized, double-blind, placebo-controlled trial of paroxetine in children and adolescents with social anxiety disorder. Arch Gen Psychiatry. 2004;61(11):1153–62.
9. Jeffrey RS, Jeffrey AM, Heidi S, Sarah AM, Sara TV, Laura BR, et al. Escitalopram in adolescents with generalized anxiety disorder: a double-blind, randomized, placebo-controlled study. J Clin Psychiatry. 2020;81(5):6584.
10. Emslie GJ, Ventura D, Korotzer A, Tourkodimitris S. Escitalopram in the treatment of adolescent depression: a randomized placebo-controlled multisite trial. J Am Acad Child Adolesc Psychiatry. 2009;48:721–9.
11. Onrust SV, McClellan k. Perospirone. CNS Drugs. 2001;15(4):329–37.
12. Terufumi K, Akira H, Yukihiro O, Hiroshi S, Hiroyasu T, Mitsutaka N. Binding profile of SM-9018, a novel antipsychotic candidate. Japanese J Pharmacol. 1990;54(4):478–81.
13. David HO, Randall CC, Richard LG 2nd, Sandra EF, Darin JK, Lewis SS. Involvement of 5-HT1A receptors in animal tests of anxiety and depression: evidence from genetic models. Stress. 2003;6(2):101–10.
14. Araneda R, Andrade R. 5-Hydroxytryptamine2 and 5-hydroxytryptamine 1A receptors mediate opposing responses on membrane excitability in rat association cortex. Neuroscience. 1991;40(2):399–412.
15. Ashby CR, Edwards E, Wang RY. Electrophysiological evidence for a functional interaction between 5-HT1A and 5-HT2A receptors in the rat medial prefrontal cortex: an iontophoretic study. Snapse. 1994;17(3):173–81.
16. Hisato M, Tokuzo M, Kenzo O, Kenya O, Kauhisa H, Kensei M, et al. A benzothiazole derivative and antipsychotic agent, perospirone, for augmentation of selective serotonin reuptake inhibitors (SSRIs) in refractory obsessive-compulsive disorder (OCD): two patient case series. Int J Psychiatry Clin Pract. 2006;10(2):142–5.
17. Tatsui O, Takashi T, Naoya S, Kumi U, Asuka Y, Aya K, et al. Perospirone augmentation of paroxetine in treatment of refractory obsessive-compulsive disorder with depression. Prog Neuropsychopharmacol Biol Psychiatry 2007;30(31)(2):564–6, 566.
18. Yasushi S, Norio YF, Taku N, Manabu S, Sunao K. Augmentation of antidepressants with perospirone for treatment-resistant major depressive disorder. Clinical trial. Prog Neuropsychopharmacol Biol Psychiatry. 2009;33(3):416–8.
19. Torgny HS. Alpha-adrenoceptor modulation hypothesis of antipsychotic atypicality. Prog Neuropsychopharmacol Biol Psychiatry. 2003;27(7):1145–58.
20. Marilyn AD, Douglas JS, Bryan LR. Aripiprazole: a novel atypical antipsychotic drug with a uniquely robust pharmacology. CNS Drug Rev. 2004;10(4):317–36.
21. Paul JG, Jason MJ. Aripiprazole: profile on efficacy and safety. Expert Opin Pharmacother. 2002;3(12):1773–81.
22. Hamik A, Oksenberg D, Fischette C, Peroutka SJ. Analysis of tandospirone (SM-3997) interactions with neurotransmitter receptor binding sites. Biol Psychiatry. 1990;28:99–109.
23. Xuev S. Ickowicz a: serotonin syndrome in children and adolescents exposed to selective serotonin reuptake inhibitors – a review of literature. J Can Acad Child Adolesc Psychiatry. 2021;30(3):156–64.

How to cite this article: Miyazaki K. Perospirone augmentation of escitalopram in the treatment of an adolescent sophophobia (fear of learning) patient. Neuropsychopharmacol Rep. 2022;42:374–376. https://doi.org/10.1002/npr.212256